Intetumumab

Intetumumab

Intetumumab

Monoclonal antibody

Intetumumab is a human monoclonal antibody targeting integrins[1] that was being studied for the treatment of solid tumors.[2]

Quick Facts Monoclonal antibody, Type ...

Intetumumab was developed by Centocor, Inc.

Phase II clinical trials for treatment of melanoma and prostate cancer were in progress when development of the drug was discontinued.[3]

References

  1. [1]
    Łasiñska I, Mackiewicz J (2019). "Integrins as A New Target for Cancer Treatment". Anti-Cancer Agents in Medicinal Chemistry. 19 (5): 580–586. doi:10.2174/1871520618666181119103413. PMID 30451118. S2CID 53952455.
  2. [2]
    "Statement On A Nonproprietary Name Adopted By The USAN Council: Intetumumab" (PDF). American Medical Association.
  3. [3]
    "Intetumumab". AdisInsight. Retrieved 30 January 2017.


Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Intetumumab, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.